Moleculin Biotech, Inc. (MBRX)
MBRX Stock Price Chart
Explore Moleculin Biotech, Inc. interactive price chart. Choose custom timeframes to analyze MBRX price movements and trends.
MBRX Company Profile
Discover essential business fundamentals and corporate details for Moleculin Biotech, Inc. (MBRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Jun 2016
Employees
17.00
Website
https://www.moleculin.comCEO
Walter V. Klemp
Description
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
MBRX Financial Timeline
Browse a chronological timeline of Moleculin Biotech, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$1.61.
Earnings released on 14 May 2026
EPS came in at -$3.54 falling short of the estimated -$1.69 by -109.47%.
Earnings released on 20 Mar 2026
EPS came in at $2.61 surpassing the estimated -$7.77 by +133.59%.
Stock split effective on 1 Dec 2025
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2025
EPS came in at -$3.25 surpassing the estimated -$5.00 by +35.00%.
Earnings released on 12 Aug 2025
EPS came in at -$12.25 falling short of the estimated -$9.75 by -25.64%.
Earnings released on 13 May 2025
EPS came in at -$17.25 surpassing the estimated -$17.75 by +2.82%.
Earnings released on 21 Mar 2025
EPS came in at -$0.37 surpassing the estimated -$1.54 by +75.97%.
Earnings released on 11 Nov 2024
EPS came in at -$2.85 falling short of the estimated -$2.44 by -16.80%.
Earnings released on 13 Aug 2024
EPS came in at -$55.75 falling short of the estimated -$52.50 by -6.19%.
Earnings released on 10 May 2024
EPS came in at -$50.50 surpassing the estimated -$89.75 by +43.73%.
Earnings released on 22 Mar 2024
EPS came in at -$5.02 falling short of the estimated -$3.05 by -64.59%.
Stock split effective on 22 Mar 2024
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2023
EPS came in at -$71.21 surpassing the estimated -$78.71 by +9.53%.
Earnings released on 11 Aug 2023
EPS came in at -$74.96 surpassing the estimated -$104.95 by +28.58%.
Earnings released on 11 May 2023
EPS came in at -$104.95 falling short of the estimated -$93.70 by -12.01%.
Earnings released on 22 Mar 2023
EPS came in at -$89.96 surpassing the estimated -$104.95 by +14.28%.
Earnings released on 10 Nov 2022
EPS came in at -$112.44 falling short of the estimated -$101.20 by -11.11%.
Earnings released on 15 Aug 2022
EPS came in at -$89.96 surpassing the estimated -$93.70 by +3.99%.
Earnings released on 11 May 2022
EPS came in at -$89.96 falling short of the estimated -$78.71 by -14.29%.
Earnings released on 25 Mar 2022
EPS came in at -$63.72 surpassing the estimated -$78.71 by +19.04%.
Earnings released on 11 Nov 2021
EPS came in at -$56.22 surpassing the estimated -$74.96 by +25.00%.
Earnings released on 12 Aug 2021
EPS came in at -$71.21 surpassing the estimated -$74.96 by +5.00%.
MBRX Stock Performance
Access detailed MBRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
